NPR tells the exclusive, behind-the-scenes story of the first person with a genetic disorder to be treated in the United States with the revolutionary gene-editing technique CRISPR.
Black scientists more often seek grants for community health studies, but molecular-level research proposals win more funding. More diversity throughout the process could help close the gap, says NIH.
During the 1980s and early 1990s, Rep. John Dingell was instrumental in expanding the Medicaid program, reshaping Medicare and modernizing the Food and Drug Administration. He died Thursday night.
After trying one treatment after another for his leukemia, 20-year old Aaron Reid enrolled in a study to test an experimental therapy using modified cells from his own body.
Researchers are working on better ways to teach patients' immune systems to root out and kill malignant cells. A promising approach involves cells that attack cancer two ways at one time.
Scientists and National Institutes of Health officials met with alcohol company executives and appeared to solicit money from them in violation of government policy. The NIH canceled the study.
Public health interventions and antiviral drugs have put HIV on the ropes in the U.S. But it's unlikely that infections can be wiped out without a vaccine.
The Senate agreement is now before the House, which needs to act by midnight to avert a shutdown. The deal appears to include almost every health priority Democrats have been pushing in recent months.
Federal researchers are collecting blood samples from 1 million Americans as part of an effort called "precision medicine." But some critics worry that the path ahead is expensive and unclear.
If the former drug company executive is confirmed by the Senate, he would replace Dr. Tom Price, who resigned in September after a scandal involving government travel on private aircraft.
One California university is trying a new strategy to help minority students perform better in STEM classes and develop the mental resilience to face future challenges.
The relationship has been fraught with disputes about which research should be funded. Four House members have asked NFL Commissioner Roger Goodell whether the league plans to honor its commitment.
Three genetic changes could be enough to make a bird flu strain that's already killing some people in China highly contagious. Are experiments with a deliberately mutated version too risky?
Some members of Congress say the U.S. government should use the patent rights it owns for any drugs that were developed with federal grants to drive down the prices of those drugs.
The National Institutes of Health, which funds research in treatments and cures, could lose 20 percent of its budget under the administration's proposal. More money would go for addiction treatment.
Sweeping legislation that would reshape how the Food and Drug Administration reviews new products and bolster National Institutes of Health funding is moving closer to becoming law. What's at stake?
The House could vote Wednesday on a vast bill that stretches nearly a thousand pages and holds changes large and small for the National Institutes of Health and the Food and Drug Administration.
More than 1,455 lobbyists weighed in on the 21st Century Cures Act in this congressional cycle. Only one health bill since 2011 has garnered more attention.
The federal government spends more than $30 billion a year to fund the National Institutes of Health. How will a new administration affect academic research? What about pharmaceutical research?
The aim is to make clinical trial data available to volunteers and scientists, even if a drug or therapy being tested turns out to be a failure. That could help identify serious side effects.
There's scant science to support the ancient Eastern therapy of cupping. But that hasn't stopped Olympians from trying it to ease pain and speed recovery.
The National Institutes of Health proposed lifting its moratorium on funding for research on part-animal, part-human embryos — which raises a huge dilemma, says bioethicist Insoo Hyun.
The National Institutes of Health is proposing to fund experiments that create chimeras of human and animal cells while also imposing restrictions in response to ethical concerns.
NIH Director Francis Collins has stopped research at two leading labs for now. But an independent board of experts wants even more oversight to ensure patient safety is the top priority.
The National Institutes of Health shut down some clinical trials and two production facilities over concerns that safety rules haven't been followed, but it says no patients appear to have been hurt.
